Biologics Market (Product - Monoclonal Antibodies, Vaccines, Recombinant Proteins, and Others (antisense, RNAi & Molecular Therapy Products); Therapy Areas - Autoimmune, Antidiabetics, Oncologics, and Others): Global Industry Analysis, Trends, Size, Share and Forecasts to 2026. The global biologics market is projected to grow at a CAGR of 10.7% over the forecast period of 2020-2026.
Pune, India -- (SBWIRE) -- 05/21/2020 -- Infinium Global Research's recent report on the "Biologics Market (Therapy Areas (Autoimmune, Antidiabetics, Oncologics, and Others) product (Monoclonal Antibodies, Vaccines, Recombinant Proteins and others): Global Industry Analysis, Trends, Size, Share and Forecasts to 2026." provides a comprehensive outline of the factors responsible for the growth of the market.
We are Now Including the Impact Analysis of the COVID-19 on this Premium Report and the Forecast Period of this Report shall be Revised to 2020-2026.
The Section on the Impact of COVID-19 on this Market is Included in the Report for Free. To Know More Request Sample of this Report: https://www.infiniumglobalresearch.com/reports/sample-request/19870
In recent years, the pharmaceutical industry has been transformed by the development of biologic medicines. Biologics are also projected to comprise seven of the top ten global pharmaceuticals and account for up to 30 percent of pharmaceuticals under development. These drugs include infliximab (Remicade), abatacept (Orencia), ritumximab (Rituxan), tocilizumab (Actemra), and golimumab (Simponi Aria) becoming critical for the treatment of inflammatory arthritis, inflammatory bowel disease, psoriasis, and other conditions.
Moreover, biologics are emerging as a therapy area for diseases such as asthma, dyslipidaemia, and allergy. They will expand treatment options for patients in these indications, many of which are underserved, which will further augment the growth of the biologics market.
The current concerns over the spread of coronavirus are expected to have a modest impact on the growth of the biologics market as these biologics are considered immunosuppressing because they work on different immune system pathways to curtail the inflammation that occurs in these chronic conditions, which can make patients more vulnerable to different kinds of infection, which is likely to lower its adoption. However, there will be enough latent market potential waiting to be exploited in the field of biologics for the treatment of COVID-19 through developmental efforts.
Demand for Monoclonal Antibodies to Intensify over the Forecast Years
Currently, mAbs hold the dominant share of the biologic market sales and remain the largest technology class within the biologic pipeline. However, the mAb dominance we see today could be outperformed by novel biologic technologies currently in the pipeline. In the next ten years, therapies using non-established technologies will have launched into the market.
There are four technology classes such as Antibody-drug conjugates, Antisense/RNAi, Gene Therapy, and Cell Therapy with a significant pipeline scale which will be entering a pivotal stage during their first few launches by 2020. The report on the "Global Biologics Market" offers an in-depth analysis of the segments such as Therapy Areas (Autoimmune, Antidiabetics, Oncologic, and Others) and product (Monoclonal Antibodies, Vaccines, Recombinant Proteins, and others).
Get this Section as a Free Customization in the Report along with a 30% Discount on the Study: https://www.infiniumglobalresearch.com/reports/customization/19870
"We have Decided to Extend our Support to the Industry on Account of Corona Outbreak by Offering Flat Discount 30% on All Our Studies and Evaluation of the Market Dynamics in Global on Biologics Market Amidst COVID-19."
Asia Pacific Region to Grow at the Highest CAGR in the Global Biologics Market
Geographically, the largest revenue was generated in North America. The US is the major contributing country in this region due to favorable regulatory policies, growing technological advancements, and increasing awareness about the biologics in this country. Furthermore, Europe is expected to hold a major share due to the presence of several pharma giants in the European countries along with research and development infrastructure.
Moreover, Asia Pacific is expected to grow at the fastest pace due to the low manufacturing cost and the availability of low-cost labor. The growing pharmaceutical industry in India and China is also expected to attract more established players in the region, which will enhance the growth of the Asia-Pacific biologics market over the forecast years.
Biologics Market to Witness Launch of Several Novel Drugs Over the Forecast Years
The markets for biologics are increasingly dominated by international players. The major players in the market include Eli Lilly & Company, Samsung Biologics, F Hoffman La Roche, Celltrion, Addgene, Amgen, and Abbvie Inc. These players in the biologics market are engaged in product diversification and bringing innovations in their products.
Much of the work for innovative biologic delivery has been in the diabetes space. This is because diabetes is a primary care area with an extremely large and growing patient population that could see the significant benefits and increased compliance of insulin treatment should it be made easier. Once established, these technologies could spread to other disease areas.
However, the growing demand for innovation has also created a beneficial opportunity for new entrants trying to penetrate into the market. The report delivers insights into the leading players that have contributed greatly to the growth of the market and also estimates the impact of product innovations, similar to that of the aforementioned product on the global market.
Browse Detailed Report@ https://www.infiniumglobalresearch.com/healthcare-medical-devices/global-biologics-market
About Infinium Global Research
Infinium Global Research is a business consulting and market research firm; a group of experts that caters to fulfilling business and market research needs of leading companies in various industry verticals and business segments. The company also serves government bodies, institutes and non-profit/non-government organizations to meet their knowledge and information needs.
Through our information services and solutions, we assist our clients to improve their performance and assess the market conditions to achieve their organizational goals. Our team of experts and analysts are engaged in continuously monitoring and assessing the market conditions to provide knowledge support to our clients. To help our clients and to stay updated with the advances and inventions in technology, business processes, regulations and environment, Infinium often conducts regular meets with industry experts and opinion leaders. Our key opinion leaders are involved in monitoring and assessing the progress in the business environment, so as to offer the best opinion to our clients.